UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 1, 2019
 
DARÉ BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
 
001-36395
 
20-4139823
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(I.R.S. Employer
Identification No.)
 
3655 Nobel Drive, Suite 260
San Diego, CA 92122
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code: (858) 926-7655
 
Not Applicable
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company   x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   x






Item 8.01
Other Events
Compliance with Nasdaq Minimum Bid Price Rule
On April 1, 2019, Daré Bioscience, Inc. (“Daré”) was informed by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC that Daré regained compliance with the minimum bid price requirement in Nasdaq Listing Rule 5550(a)(2) as a result of the closing bid price of Daré’s common stock being $1.00 per share or greater for the 10 consecutive business day period from March 18, 2019 to March 29, 2019. As previously reported, Daré was not in compliance with the minimum bid price requirement because the closing bid price for its common stock was less than $1.00 for the 30 consecutive business days preceding November 30, 2018 . That matter is now closed.
Daré issued a press release regarding it regaining compliance with the minimum bid price requirement, a copy of which is included as Exhibit 99.1 to this report.
Corporate Presentation
Included as Exhibit 99.2 to this report is a presentation about Daré and its product candidates, dated April 1, 2019, which is incorporated herein by reference. Daré intends to use the presentation and its contents in various meetings with investors, securities analysts and others, commencing on April 1, 2019.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits.






SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
 
 
 
 
 
 
 
 
 
 
 
DARÉ BIOSCIENCE, INC.
 
 
 
 
Dated: April 1, 2019
 
 
 
By:
 
/s/ Sabrina Martucci Johnson
 
 
 
 
Name:
 
Sabrina Martucci Johnson
 
 
 
 
Title:
 
President and Chief Executive Officer



Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Dare Bioscience Charts.
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Dare Bioscience Charts.